Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 432c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($4.32). Revenue for the quarter came in at $37.93 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Stay long AI-capex winners into the peak, Stifel says despite bubble fears
• Crown Crafts (CRWS) Reports Q4 EPS of $0.03
• Lenovo expands hybrid AI portfolio with new inferencing platforms